Increases in Reimbursement for Brand-Name Drugs in Part D (OEI-03-15-00080) |
Spending Trends |
2018/06 |
Medicare Part D |
CMS Did Not Always Provide Accurate Medicaid Unit Rebate Offset Amounts to State Medicaid Agencies (A-07-17-06074) |
Program Compliance |
2018/05 |
Medicaid |
Potential Misclassifications Reported by Drug Manufacturers May Have Led to $1 Billion in Lost Medicaid Rebates (OEI-03-17-00100) |
Data Integrity |
2017/12 |
Medicaid |
Excluding Non-covered Versions When Setting Payment for Two Part B Drugs Would Have Resulted in Lower Drug Costs for Medicare and its Beneficiaries (OEI-12-17-00260) |
Reimbursement Policy |
2017/11 |
PART B |
Reasonable Assumptions in Manufacturer Drug Price Reporting Under Medicaid (OEI-12-17-00130) |
Data Integrity |
2019 |
Medicaid |
FDA Approval Status of Drugs in the Medicaid Drug Rebate Program (OEI-03-17-00120) |
Data Integrity |
2019 |
Medicaid |
The Impact of Authorized Generics on Medicaid Drug Rebates (W-00-18-31499) |
Data Integrity, Program Compliance |
2019 |
Medicaid |
Accuracy of Drug Categorizations for Medicaid Rebates (OEI-03-08-00300) |
Data Integrity |
2009/07 |
Medicaid |
Average Manufacturer Price Determinations by Selected Drug Manufacturers Generally Were Consistent with Federal Requirements (A-06-13-00014) |
Data Integrity, Program Compliance |
2014/06 |
Medicaid |
Drug Manufacturers� Non-Compliance with AMP Reporting Requirements (OEI-03-09-00060) |
Program Compliance, Data Integrity |
2010/09 |
Medicaid |
Limitations in Manufacturer Reporting of Average Sales Price Data for Part B Drugs (OEI-12-13-00040) |
Data Integrity, Program Compliance |
2014/07 |
Medicare Part B |
Quality of Sponsor Data Used in Calculating Coverage Gap Discounts (A-07-16-06067) |
Data Integrity, Program Compliance |
2019 |
Medicare Part D |
Concerns with Rebates in the Medicare Part D Program (OEI-02-08-00050) |
Incentive Alignment |
2011/03 |
Medicare Part D |
States' Collection of Rebates for Physician-Administered Drugs (OEI-03-09-00410) |
Program Compliance |
2011/06 |
Medicaid |
Annual Fee on Branded Prescription Drug Companies Under the Affordable Care Act (OEI-03-12-00560) |
Program Compliance |
2014/04 |
Medicare Part D |
States' Collection of Offset and Supplemental Medicaid Rebates (OEI-03-12-00520) |
Program Compliance |
2014/12 |
Medicaid |
States' Collection of Rebates for Drugs Paid Through Medicaid Managed Care Organizations Has Improved (OEI-05-14-00431) |
Program Compliance |
2015/09 |
Medicaid |
Medicaid Drug Rebate Dispute Resolution Could Be Improved (OEI-05-11-00580) |
Program Compliance, Data Integrity |
2014/08 |
Medicaid |
State Efforts to Exclude 340B Drugs from Medicaid Managed Care Rebates (OEI-05-14-00430) |
Program Compliance, Data Integrity |
2016/06 |
Medicaid |
States' Collection of Medicaid Rebates for Physician-Administered Drugs |
Program Compliance |
Various |
Medicaid |
Medicare Part D Rebates Related to Drugs Dispensed by 340B Pharmacies |
Reimbursement Policy |
2019 |
Medicare Part D |
Least Costly Alternative Policies: Impact on Prostate Cancer Drugs Covered Under Part B (OEI-12-12-00210) |
Reimbursement Policy |
2012/11 |
Medicare Part B |
Medicare Could Collect Billions If Manufacturers Were Required To Pay Rebates for Part B Drugs (OEI-12-12-00260) |
Reimbursement Policy |
2013/09 |
Medicare Part B |
Update: Medicare Payments for End Stage Renal Disease Drugs (OEI-03-12-00550) |
Spending Trends, Reimbursement Policy |
2014/03 |
Medicare Part B |
Medicaid Drug Pricing in State Maximum Allowable Cost Programs (OEI-03-11-00640) |
Reimbursement Policy |
2013/08 |
Medicaid |
Medicaid Rebates for Brand-Name Drugs Exceeded Part D Rebates by a Substantial Margin (OEI-03-13-00650) |
Reimbursement Policy |
2015/04 |
Medicare Part D |
Part B Payments for 340B Purchased Drugs (OEI-12-14-00030) |
Reimbursement Policy |
2015/11 |
Medicare Part B |
CMS Should Address Medicare's Flawed Payment System for DME Infusion Drugs (OEI-12-16-00340) |
Reimbursement Policy |
2016/09 |
Medicare Part B |
Average Manufacturer Prices Increased Faster Than Inflation for Many Generic Drugs (A-06-15-00030) |
Spending Trends, Reimbursement Policy |
2015/12 |
Medicaid |
Calculation of Potential Inflation-Indexed Rebates For Medicare Part B Drugs 2017 (OEI-12-17-00180) |
Reimbursement Policy, Spending Trends |
2017 |
Medicare Part B |
Specialty Drug Pricing and Reimbursement in Medicaid (OEI-03-17-00430) |
Spending Trends, Reimbursement Policy |
2019 |
Medicaid |
High-Price Drugs are Increasing Federal Payments for Medicare Part D Catastrophic Coverage (OEI-02-16-00270) |
Spending Trends |
2017/01 |
Medicare Part D |
Replacing Average Wholesale Price: Medicaid Drug Payment Policy (OEI-03-11-00060) |
Reimbursement Policy |
2011/07 |
Medicaid |
Analyzing Changes to Medicaid Federal Upper Limit Amounts (OEI-03-11-00650) |
Reimbursement Policy |
2012/10 |
Medicaid |
Beneficiary Utilization of Albuterol and Levalbuterol Under Medicare Part B (OEI- 03-07-00440) |
Reimbursement Policy, Spending Trends |
2009/08 |
Medicare Part B |
Calculation of Volume Weighted Average Sales Price for Medicare Part B Prescription Drugs (OEI-03-05-00310) |
Data Integrity |
2006/02 |
Medicare Part B |
High Part D Spending on Opioids and Substantial Growth in Compounded Drugs Raise Concerns (OEI-02-16-00290) |
Spending Trends |
2016/06 |
Medicare Part D |
Accuracy of Part D Plans' Drug Prices Provided on the Medicare Prescription Drug Plan Finder (OEI-03-07-00600) |
Data Integrity |
2009/07 |
Medicare Part D |
Medicare Payments for Newly Available Generic Drugs (OEI-03-09-00510) |
Reimbursement Policy |
2011/01 |
Medicare Part B |
Medicaid Brand-Name Drugs: Rising Prices Are Offset by Manufacturer Rebates (OEI-03-10-00260) |
Reimbursement Policy |
2011/08 |
Medicaid |
Medicare Payments for Drugs Used to Treat Wet Age-Related Macular Degeneration (OEI-03-10-00360) |
Reimbursement Policy |
2012/04 |
Medicare Part B |
Medicaid Rebates for Physician-Administered Drugs (OEI-03-02-00660) |
Program Compliance |
2004/04 |
Medicaid |
Average Sales Prices: Manufacturer Reporting and CMS Oversight (OEI-03-08-00480) |
Program Compliance, Reimbursement Policy |
2010/02 |
Medicare Part B |
Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs (OEI-05-12-00540) |
Program Compliance, Data Integrity |
2014/09 |
Medicare Part D |
Medicare Part B Prescription Drug Dispensing and Supplying Fee Payment Rates Are Considerably Higher Than the Rates Paid by Other Government Programs (A-06-12-00038) |
Reimbursement Policy |
2014/09 |
Medicare Part B |
Review of Additional Rebates for Brand-Name Drugs with Multiple Versions (A-06-09-00033) |
Reimbursement Policy |
2010/03 |
Medicaid |
Gaps in Oversight of Conflict of Interest in Medicare Prescription Drug Decisions (OEI-05-10-00450) |
Incentive Alignment |
2013/03 |
Medicare Part D |
Contract Pharmacy Arrangements in the 340B Program (OEI-05-13-00431) |
Program Compliance |
2014/02 |
340B |
Congressionally Mandated ASP/AMP Comparisons |
Data Integrity |
Ongoing |
Medicare Part B |
Congressionally Mandated ASP/AMP Comparisons |
Data Integrity |
Various |
Medicare Part B |
Medicare Part B Overpaid Millions for Selected Outpatient Drugs (A-09-14-02024) |
Program Compliance |
2015/07 |
Medicare Part B |